Psoriasis

Common Name(s)

Psoriasis

Psoriasis is a chronic (long-lasting) skin condition that causes cells to grow too quickly and results in red, scaly, and occasionally itchy patches on the skin. In normal skin, cells flake off from the surface and are replaced by new cells every four weeks. In people with psoriasis, new cells form and quickly move to the surface of the skin, forming thick patches (plaques) that typically appear on the elbows, knees, scalp, lower back, hands, or feet. These patches are usually dry and itchy. If scraped or picked, they can also bleed. In some cases of psoriasis, the areas where bones meet (joints) may also become swollen and stiff, which is called psoriatic arthritis. Psoriasis can be mild, causing small areas of rash, or severe, causing large areas of raised, red and loose plaques. Symptoms of psoriasis tend to come and go. Risk factors that can lead to the return of symptoms (flare-ups) include a dry climate, infections, stress, dry skin and certain medications.

The exact cause of psoriasis is unknown. However, it is thought to be an autoimmune disease, which means something causes the body’s immune system to attack itself, mistaking healthy cells for something foreign (from outside the body). It is believed that both genetic and environmental factors play a role in psoriasis. In order to diagnose psoriasis, your doctor will gather a medical history and perform a physical exam that focuses on the skin. Your doctor may also remove and examine a small piece of the affected skin (skin biopsy). There is no cure for psoriasis. However, there are many treatment options that may help control the symptoms. These include creams that can be applied to the surface of the skin (topical), oral medications, moisturizers, and light therapy. If you or your child have been diagnosed with psoriasis, talk with your doctor to decide which treatment option is best for you.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Psoriasis" for support, advocacy or research.

National Psoriasis Foundation

Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

Last Updated: 26 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Psoriasis" for support, advocacy or research.

National Psoriasis Foundation

Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

http://www.psoriasis.org/

Last Updated: 26 Jul 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

General Resources

For scientists and medical professionals

Information about how to apply for National Psoriasis Foundation research grants and fellowships, our medical journal and other science-related materials for medical professionals.

Updated 15 Nov 2012

Go To URL
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Psoriasis" returned 2169 free, full-text research articles on human participants. First 3 results:

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
 

Author(s): Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun, Gregory S Cameron, Janelle Erickson, Robert J Konrad, Talia M Muram, Brian J Nickoloff, Olawale O Osuntokun, Roberta J Secrest, Fangyi Zhao, Lotus Mallbris, Craig L Leonardi, , ,

Journal: N. Engl. J. Med.. 2016 Jul;375(4):345-56.

 

Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and ...

Last Updated: 28 Jul 2016

Go To URL
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
 

Author(s): Fernando Alfageme Roldán, Almudena Bermejo Hernando, José Luís Calvo González, Pilar Marqués Sánchez

Journal:

 

The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.

Last Updated: 13 Apr 2016

Go To URL
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
 

Author(s): James Krueger, James D Clark, Mayte Suárez-Fariñas, Judilyn Fuentes-Duculan, Inna Cueto, Claire Q Wang, Huaming Tan, Robert Wolk, Scott T Rottinghaus, Maryann Z Whitley, Hernan Valdez, David von Schack, Shawn P O'Neil, Padmalatha S Reddy, Svitlana Tatulych,

Journal: J. Allergy Clin. Immunol.. 2016 Apr;137(4):1079-90.

 

Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.

Last Updated: 9 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Psoriasis" returned 301 free, full-text review articles on human participants. First 3 results:

Psoriasis: new comorbidities.
 

Author(s): Jackson Machado-Pinto, Michelle dos Santos Diniz, Nádia Couto Bavoso

Journal: An Bras Dermatol. ;91(1):8-14.

 

Psoriasis is a chronic inflammatory disease associated with several comorbidities. A few decades ago, it was considered an exclusive skin disease but today it is considered a multisystem disease. It is believed that 73% of psoriasis patients have at least one comorbidity. Studies ...

Last Updated: 17 Mar 2016

Go To URL
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
 

Author(s): V Di Lernia, F Bardazzi

Journal:

 

The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal ...

Last Updated: 18 Feb 2016

Go To URL
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
 

Author(s): Alessandro Mantovani, Paolo Gisondi, Amedeo Lonardo, Giovanni Targher

Journal:

 

Over the past 10 years, it has become increasingly evident that nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects multiple extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways. In this review we ...

Last Updated: 10 Feb 2016

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
 

Status: Recruiting

Condition Summary: Psoriasis

 

Last Updated: 6 Jun 2016

Go to URL
The Association Between Psoriasis and Intestinal Bacterial Population
 

Status: Not yet recruiting

Condition Summary: Psoriasis

 

Last Updated: 16 Apr 2015

Go to URL
Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
 

Status: Recruiting

Condition Summary: Psoriasis

 

Last Updated: 22 Sep 2016

Go to URL